Skip to main content
OpenTrials
Completed

NCT Number: NCT03886987

Skin Sensitization Test (Modified Draize-95 Test)

Skin Sensitization Test (Modified Draize-95 Test) to Support a Low Dermatitis Potential Claim for a Blue Non Sterile Powder Free Nitrile Examination Gloves. This study is a RIPT (Repeat Insult Patch Test) to evaluate whether residual chemical additives at the level that may induce Type IV allergy in the nonsensitized general user population are present in a finished Blue Non Sterile Powder Free Nitrile Examination Glove.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Consumer Product Testing Company, Inc.

Fairfield, New Jersey, 07004, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must be aged 18 to 65 years, inclusive;
  • Subjects who have not participated in other voluntary testing for at least 30 days;
  • Subjects must execute an Informed Consent Form that includes a HIPAA statement; and
  • Subjects must be capable of understanding and following directions.
  • Female subjects must produce a negative urine pregnancy test prior to the initiation and also at the completion of the trial.

Exclusion criteria

  • Subjects who are in ill health, as determined by the PI;
  • Subjects who are taking medication, other than birth control, which could influence the purpose, integrity or outcome of the trial;
  • Subjects who have used topical or systemic corticosteroids, anti-inflammatories, antihistamines or antibiotics within 2 weeks prior to trial initiation or during their participation on this trial;
  • Female subjects who are pregnant as evidenced by a urine pregnancy test, planning to become pregnant or lactating during the trial;
  • Subjects who have a history of adverse reactions to cosmetics, OTC drugs, or other personal care products;
  • Subjects who introduce the use of any new cosmetic, toiletry or personal care products during the trial;
  • Subjects with any visible skin disease that might be confused with skin reactions caused by the test material;
  • Subjects with any knowledge or indication of existing Type IV allergy (delayed hypersensitivity) to natural rubber chemical additives;
  • Subjects with any indication of existing Type I allergy (immediate hypersensitivity) to natural rubber proteins;
  • Subjects with a history of frequent irritation; or
  • Subjects who have received endogenous or exogenous immunosuppressive treatment (or prolonged exposure to sun).

Treatment and study plan

Blue Non Sterile Powder Free Nitrile Examination Gloves

Device

Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.

Primary outcomes

  1. Irritation scored by Erythemal Scoring Scale

    Time frame: 8 weeks

    Basic Score and Description:

    0 - No visible reaction. 0.5 - Doubtful or negligible erythema reaction. 1.0 - Mild or just perceptible macular erythema reaction in a speckled/follicular, patchy or confluent pattern (slight pinking).

    2.0 - Moderate erythema reaction in a confluent pattern (definite redness). 3.0 - Strong or brisk erythema reaction that may spread beyond the test site.

    If a subject develops a positive reaction (a score value of 1.5) to the test material or shows signs of irritation after patch applications, further patching on those individuals are stopped.

    In order to qualify for the claim of a reduced sensitization potential, all 200 individuals completing the study should exhibit a score value of no more than 1.5 based on the scoring criteria.

Sponsors and collaborators

Lead sponsor

Central Medicare Sdn. Bhd.

Industry

Collaborators

  • Consumer Product Testing Company, Inc.

Registry information

Official study title

Skin Sensitization Test (Modified Draize-95 Test) to Support a Low Dermatitis Potential Claim

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Mar 22, 2019
Registry last updated
Mar 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.